Living Cell Technologies announced that its Russian subsidiary, LCT Biomedical Limited, has received registration of the company’s groundbreaking diabetes treatment, DIABECELL, as a marketable medical technology in Russia. Registration allows for the sale and use of the DIABECELL technology in the treatment of type 1 diabetes in Russia.The type 1 diabetes treatment involves inserting insulin-producing pig cells (islet cells) into the pancreas to replace the patient’s own cells. The cells are implanted into the abdomen of patients using a simple laparoscopic procedure, and work by self-regulating and efficiently secreting insulin in the patient’s body.
The registration was granted following clinical trials conducted in Russia with patients suffering from insulin dependent type 1 diabetes. The trials demonstrated that treatment safely reduces a patient’s need for insulin.
Source: http://www.lctglobal.com/
